NextCell Pharma AB (STO:NXTCL)

Market Cap	36.21M -64.0%
Revenue (ttm)	10.78M +5.3%
Net Income	-42.11M
EPS	-0.33
Shares Out	126.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	549,538
Open	0.2305
Previous Close	0.2535
Day's Range	0.2305 - 0.3000
52-Week Range	0.2000 - 1.7840
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NXTCL

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 3, 2026

Data Sources Report a data error